Biogen is bolstering the company’s multiple sclerosis pipeline through a licensing agreement with Maine-based MedRhythms for its investigational digital therapeutic MR-004, which is being assessed for the potential treatment of gait deficits in MS.
Roche warned that Russia’s attack on Ukraine is disrupting the development of a new generation of multiple sclerosis (MS) drugs as the industry has come to disproportionately rely on Eastern Europe for clinical trials.
New research out of Harvard University strongly suggests that infection with the Epstein-Barr virus (EBV) is the leading cause of a debilitating disease of the brain and CNS – multiple sclerosis.
Clarivate Analytics pegged 11 drugs set to enter the market during 2020 as potential blockbusters by 2024
Biogen successfully fended off a patent challenge from generic company Mylan over the multiple sclerosis (MS) drug Tecfidera.
The Assistance Fund will pay $4 million to resolve claims that the Florida-based charity acted as a conduit for companies including Biogen Inc. and Novartis AG to pay kickbacks to Medicare patients using their high-priced multiple sclerosis drugs, the U.S. Justice Department said.
Swiss drugmakers Novartis and Lonza separately deepened the companies’ push into so-called biosimilars, betting cheaper copies of name-brand drugs will make headway among cost-conscious insurers and governments.
Roche lifted the company’s full-year sales outlook after revenue in first-half 2019 rose 18 percent, helped by newer drugs including the MS medicine Ocrevus and the cancer immunotherapy Tecentriq.
Mallinckrodt Plc tentatively agreed to pay $15.4 million to resolve a U.S. Justice Department probe into how a drugmaker that the company now owns marketed an expensive treatment for a rare infant seizure disorder and multiple sclerosis.
Mallinckrodt Plc filed a lawsuit against the U.S. Department of Health and Human Services and forecast an about 10 percent hit to annual net sales of the company’s gel used to treat multiple sclerosis symptoms following changes to Medicaid rebate calculations, sending shares plunging as much as 34 percent.